Free Trial

KALA BIO Q1 2024 Earnings Report

KALA BIO logo
$5.92 -0.08 (-1.33%)
(As of 12/20/2024 05:16 PM ET)

KALA BIO EPS Results

Actual EPS
-$4.20
Consensus EPS
-$2.89
Beat/Miss
Missed by -$1.31
One Year Ago EPS
N/A

KALA BIO Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

KALA BIO Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here << 

KALA BIO Earnings Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Kala Bio Advances PCED Treatment Amid Financial Update
See More KALA BIO Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like KALA BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KALA BIO and other key companies, straight to your email.

About KALA BIO

KALA BIO (NASDAQ:KALA), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

View KALA BIO Profile

More Earnings Resources from MarketBeat

Upcoming Earnings